International Journal of Hematology

, Volume 79, Issue 3, pp 253–259 | Cite as

Markers of endothelial and in vivo platelet activation in patients with essential thrombocythemia and polycythemia vera

  • Marina Karakantza
  • Nikolaos C. Giannakoulas
  • Panagiotis Zikos
  • George Sakellaropoulos
  • Alexandra Kouraklis
  • Anthi Aktypi
  • Ioannis C. Metallinos
  • Eleni Theodori
  • Nicholas C. Zoumbos
  • Alice Maniatisa
Case Report


We investigated endothelial and in vivo platelet activation in a cohort of 52 patients with essential thrombocythemia (ET) and polycythemia vera (PV) before and after cytoreductive treatment, 22 healthy controls, and 17 patients with acute cerebrovascular ischemia (ACVI) and normal platelet counts.We measured platelet expression of CD62P and CD63 antigens and levels of soluble vascular cell adhesion molecule 1 (sVCAM-1).We found increased in vivo platelet activation in all patients with ET and PV, both before and after cytoreductive treatment, compared with controls. In patients with arterial thrombosis, platelet expression of CD62P, and in patients with erythromelalgia, expression of both markers was higher compared with expression in patients without thrombotic complications. In patients with ET and PV before and after treatment, sVCAM-1 expression was increased compared with expression in controls but also compared with expression in patients with ACVI and normal platelet counts. In patients with arterial thrombosis and erythromelalgia, in vivo platelet activation correlated with the level of sVCAM-1. Our findings indicated that in vivo platelet activation reflects intrinsic platelet defects in patients with ET and PV, persists after cytoreductive treatment, and results in endothelial damage, probably through release of angiogenic factors and/or activation of white blood cells.

Key words

Platelet activation Endothelial activation Essential thrombocythemia Polycythemia vera Thrombosis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Landolfi R, Marchioli R, Patrono C. Mechanisms of bleeding and thrombosis in myeloproliferative disorders. Thromb Haemost. 1997;78:617–621.PubMedCrossRefGoogle Scholar
  2. 2.
    Schafer AI. Bleeding and thrombosis in the myeloproliferative disorders. Blood. 1984;64:1–12.PubMedGoogle Scholar
  3. 3.
    Cortelazzo S, Viero P, Finazzi G, D’Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol. 1990;8:556–562.CrossRefPubMedGoogle Scholar
  4. 4.
    Besses C, Cervantes F, Pereira A, et al. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia. 1999;13:150–154.CrossRefPubMedGoogle Scholar
  5. 5.
    Lahuerta-Palacios JJ, Bornstein R, FernáXndez-Debora FJ, et al. Controlled and uncontrolled thrombocytosis: its clinical role in essential thrombocythemia. Cancer. 1988;61:1207–1212.CrossRefPubMedGoogle Scholar
  6. 6.
    Pearson TC. Hemorheologic considerations in the pathogenesis of vascular occlusive events in polycythemia vera. Semin Thromb Hemost. 1997;23:433–439.CrossRefPubMedGoogle Scholar
  7. 7.
    Watson KV, Key N. Vascular complications of essential thrombocythaemia: a link to cardiovascular risk factors. Br J Haematol. 1993;83:198–203.CrossRefPubMedGoogle Scholar
  8. 8.
    Tefferi A. Recent progress in the pathogenesis and management of essential thrombocythemia. Leuk Res. 2001;25:369–377.CrossRefPubMedGoogle Scholar
  9. 9.
    Broughton BJ, Allington MJ, King A. Platelet and plasma β-thromboglobulin in myeloproliferative syndromes and secondary thrombocytosis. Br J Haematol. 1978;40:125–132.CrossRefGoogle Scholar
  10. 10.
    Ireland H, Lane DA, Wolff S, Foadi M. In vivo platelet release in myeloproliferative disorders. Thromb Haemost. 1982;48:41–45.PubMedGoogle Scholar
  11. 11.
    Wehmeier A, Tschöpe D, Esser J, Menzel C, Nieuwenhuis HK, Schneider W. Circulating activated platelets in myeloproliferative disorders. Thromb Res. 1991;61:271–278.CrossRefPubMedGoogle Scholar
  12. 12.
    Zahavi J, Zahavi M, Firsteter E, Frish B, Turleanu R, Rachmani R. An abnormal pattern of multiple platelet function abnormalities and increased thromboxane generation in patients with primary thrombocytosis and thrombotic complications. Eur J Haematol. 1991;47:326–332.CrossRefPubMedGoogle Scholar
  13. 13.
    Bellucci S, Ignatova E, Jaillet N, Boffa MC. Platelet hyperactivation in patients with essential thrombocythemia is not associated with vascular endothelial cell damage as judged by the level of plasma thrombomodulin, protein S, PAI-1, t-PA and vWF. Thromb Haemost. 1993;70:736–742.PubMedCrossRefGoogle Scholar
  14. 14.
    Rocca B, Ciabattoni G, Tartaglione R, et al. Increased thromboxane biosynthesis in essential thrombocythemia. Thromb Haemost. 1995;74:1225–1230.PubMedCrossRefGoogle Scholar
  15. 15.
    Griesshammer M, Beneke H, Nussbaumer B, Grünewald M, Bangerter M, Bergmann L. Increased platelet surface expression of P-selectin and thrombospondin as markers of platelet activation in essential thrombocythaemia. Thromb Res. 1999;96:191–196.CrossRefPubMedGoogle Scholar
  16. 16.
    Raszeja-Specht A, Skibowska A, Bieniaszewska M, Szutowicz A. Relationships between thrombohemorrhagic complications and platelet function in patients with essential thrombocythaemia. Am J Hematol. 2001;68:32–36.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Villmow T, Kemkes-Matthes B, Matzdorff AC. Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes. Thromb Res. 2003;108:139–145.CrossRefGoogle Scholar
  18. 18.
    Friedenberg WR, Roberts RC, David DE. Relationship of thrombohemorrhagic complications to endothelial cell function in patients with chronic myeloproliferative disorders. Am J Hematol. 1992;40:283–289.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    van Genderen PJJ, Lucas IS, van Strik R, et al. Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation. Thromb Haemost. 1996;76:333–338.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Musolino C, Alonci A, Allegra A, et al. Increased levels of the soluble adhesion molecule E-selectin in patients with chronic myeloproliferative disorders and thromboembolic complications. Am J Hematol. 1998;57:109–112.CrossRefPubMedGoogle Scholar
  21. 21.
    Musolino C, Alonci A, Bellomo G, et al. Markers of endothelial and platelet status in patients with essential thrombocythemia and polycythemia vera. Hematology. 2000;4:397–402.CrossRefPubMedGoogle Scholar
  22. 22.
    Falanga A, Marchetti M, Evangelista V, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood. 2000;96: 4261–4266.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycythemia vera based on polycythemia vera study group protocols. Semin Hematol. 1986;23:132–143.PubMedGoogle Scholar
  24. 24.
    Murphy S, Peterson P, Iland H, Laszlo J. Experience of the polycythemia vera study group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol. 1997;34:29–39.PubMedGoogle Scholar
  25. 25.
    Frezzato M, Tosetto A, Rodeghiero F. Validated questionnaire for the identification of previous personal or familial venous thromboembolism. Am J Epidemiol. 1996;143:1257–1265.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2004

Authors and Affiliations

  • Marina Karakantza
    • 1
  • Nikolaos C. Giannakoulas
    • 2
  • Panagiotis Zikos
    • 3
  • George Sakellaropoulos
    • 4
  • Alexandra Kouraklis
    • 2
  • Anthi Aktypi
    • 3
  • Ioannis C. Metallinos
    • 5
  • Eleni Theodori
    • 1
  • Nicholas C. Zoumbos
    • 2
  • Alice Maniatisa
    • 1
  1. 1.Laboratory Hematology and Transfusion MedicineMedical SchooolGreece
  2. 2.Hematology Division, Department of Internal MedicineUniversity of PatrasGreece
  3. 3.Hematology DepartmentDistrict HospitalGreece
  4. 4.Medical PhysicsUniversity of PatrasPatrasGreece
  5. 5.Neurology Departments, Medical SchoolUniversity of PatrasPatrasGreece

Personalised recommendations